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Abstract: Components with self-assembly properties derived from plant viruses provide the
opportunity to design biological nanoscaffolds for the ordered display of agents of diverse nature
and with complementing functions. With the aim of designing a functionalized nanoscaffold to target
cancer, the coat protein (CP) of Tobacco mosaic virus (TMV) was tested as nanocarrier for an insoluble,
highly hydrophobic peptide that targets the transmembrane domain of the Neuropilin-1 (NRP1)
receptor in cancer cells. The resulting construct CPL-K (CP-linker-“Kill”) binds to NRP1 in cancer cells
and disrupts NRP1 complex formation with PlexA1 as well as downstream Akt survival signaling.
The application of CPL-K also inhibits angiogenesis and cell migration. CP was also fused to a peptide
that targets the extracellular domain of NRP1 and this fusion protein (CPL-F, CP-Linker-“Find”) is
shown to bind to cultured cancer cells and to inhibit NRP1-dependent angiogenesis as well. CPL-K
and CPL-F maintain their anti-angiogenic properties upon co-assembly to oligomers/nanoparticles
together with CPL. The observations show that the CP of TMV can be employed to generate a
functionalized nanoparticle with biological activity. Remarkably, fusion to CPL allowed us to
solubilize the highly insoluble transmembrane NRP1 peptide and to retain its anti-angiogenic effect.
Keywords: plant virus; tobacco mosaic virus; nanoparticle; nanocarrier; cancer; angiogenesis;
neuropilin-1
1. Introduction
Nanoparticles play an ever-increasing role as carriers for transporting drugs to specific tissues
and cells to combat diseases [1,2], such as glioblastoma [3] and breast cancer [4] among others.
Carrier-mediated drug delivery systems can offer many advantages over delivery of a physical
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mixture of multiple drugs. The advantages include (1) prolonged half-life in the circulation provided
by the carrier, (2) reduced nonspecific uptake, (3) increased accumulation at the tumor site either
through passive enhanced permeation and retention (EPR) effects or through active targeting by
incorporation of targeting ligands, (4) endocytotic uptake, thereby bypassing multidrug resistance,
and (5) “ratio-metric-dosing”, that is, the ability to tailor the relative ratios of each agent based on its
pharmacological disposition. Moreover, a single delivery system carrying multiple drugs in the same
platform can lead to controlled and synchronised pharmacokinetics of the drugs, thus resulting in
an improved treatment efficacy. Also, a single formulation improves solubility and bioavailability.
Although many artificial nanoparticle platforms are under development [5], particular attention is
given to nanoparticles derived from plant viruses [6–11]. Virus-derived nanoparticles are particularly
attractive because they are both biocompatible and biodegradable, and their antigenicity can be
attenuated by polymer coating [12]. Viral nanoparticles can be designed and engineered by genetic
and chemical protocols. Plant viruses (unlike animal or human viruses) represent a safe platform
since they do not cause diseases in humans [13]. Their size is in the nanometer range, thus enhancing
permeability of tissues and retention in tumors [14–17]. They are suitable for both chemical and genetic
manipulation, allowing the viral coat to be tailored for specific cell or tissue types, imaging purposes,
and as a carrier for therapeutic cargo. Their multivalent nature enables the incorporation of multiple
molecules with different functions, thus allowing, for example, the combination of a cell targeting
ligand and an imaging agent on the same nanoparticle [10].
The rod-shaped Tobacco mosaic virus (TMV) has been studied for more than a century [18,19] and
is the most economically and scientifically important plant virus [20]. The virus particle is 300 nm long
and 18 nm in diameter and is composed of the 6.7 kb long viral RNA genome encapsidated by a helical
arrangement of 2130 identical copies of coat protein (CP). The protein has 158 amino acids and its
structure is known [21–25]. The particle readily assembles in vitro [26–28] with a short stretch of 432 nts
of its RNA (OAS, origin-of-assembly) being sufficient for assembly [29]. Without RNA and at neutral
pH, the CP assembles into a ”20S aggregate “, a 18 nm double “disk” (or “nano-ring”) comprising
two layers of 17 CP units, which already can be used as nanoscale scaffold. Dependent on the applied
pH, ionic strength, and temperature, the protein can also be isolated as “Protein A” (a mixture of CP
monomers, trimers, and pentamers) or helical rods of various lengths [30,31]. These assemblies can
be generated also with CP recombinantly expressed in E. coli [32–37]. The CP has several accessible
sites for chemical modification at the outer and inner surface. The protein also offers the possibility to
insert peptides at the N and C-terminus, as well as in a loop containing amino acid residues 59–66,
for display on the surface of intact virions or CP assemblies [38]. This latter property is interesting
because peptides and in particular cell-penetrating peptides have clear beneficial effects in the context
of cancer disease [39–41]. Among the different therapeutic approaches in which peptides are used,
a recent strategy involves a “membrane-targeting peptide” (MTP) of 30 amino acids that mimics the
transmembrane segment of NRP1 (MTP-NRP1). NRP1 is expressed in several human tumors where
its high levels are associated with invasive tumor growth and worsened clinical outcome [42,43].
NRP1 is also highly expressed in tumor-associated blood vessels [44]. Blocking NRP1 signaling reduces
tumor angiogenesis and tumor growth [45]. In particular, application of MTP-NRP1 was shown to
inhibit NRP1 and associated receptors, thereby blocking downstream signaling and reducing tumor
angiogenesis [46–48].
MTP-NRP1 contains a double canonical GXXXG amino acid motif (G, glycine; x, any amino acid),
known to promote and stabilize interactions between transmembrane protein helices. Any mutation
of the glycine residues in the GXXXG motif was shown to interfere with the tumor-suppressing
activity of the peptide [46]. As compared to the classical approaches with drugs that target the
extra- or intracellular domains of NRP receptors [49,50] or their ligand-binding site, inhibition of
NRP1-mediated signaling platforms by disrupting the interaction of NRP1 with itself and with other
receptors within the membrane represents a novel concept that has been proven to inhibit tumor
angiogenesis [47]. However, hydrophobic transmembrane peptides are highly insoluble in aqueous
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solutions and, therefore, require the presence of detergents for solubilization. Moreover, due to
low solubility, the production and purification of the peptides by chemical synthesis is expensive.
In addition, although MTP-NRP1 is active only upon integration into the plasma membrane and only
acts on tumors, it shows a large biodistribution profile in the whole body [47]. To improve specific
delivery at the tumor site, it is mandatory to couple this peptide to a targeting moiety that promotes its
incorporation in the membrane of target cells only. A potential additional targeting moiety that could
be combined with MTP-NRP1 is a heptapeptide (ATWLPPR; ATW-NRP1) that was shown to compete
with VEGFA165 binding to NRP1 [51]. ATW-NRP1 has already been applied in targeted photodynamic
therapy by using it for the specific delivery of the photosensitizer to the tumor site, which improved
the efficiency of tumor reduction [52,53].
Here, we show a new method for mass production and purification of the highly hydrophobic
MTP-NRP1 by fusing it to the CP of TMV (CPL-K, for CP-linker-“kill”). This method was also
used to produce a CP fusion protein displaying three copies of ATW-NPR1 in tandem (CPL-F,
for CP-linker-“find”). We demonstrate that the fusion proteins are functional and can be assembled
into disks, thus leading to the possibility to create multifunctional plant virus-derived nanoparticles in
which the function of the different peptides can be used in a combined “find and kill” strategy, thereby
enabling the delivery of biologically active peptides to target NRP1-expressing cells.
2. Results
2.1. Characterization of Coat Protein (CP) Fusion Proteins Produced in Bacteria
Fusion proteins consisting of CP fused to a linker (L, (GGGGS)3) and to the specific peptide at the
C-terminus and to a poly-histidine-(His6)-maltose-binding-protein (MBP)-tag at the N-terminus were
expressed in E. coli and purified on MBP Trap HP columns. As shown in Figure 1a,b, the isolated CP
fusion proteins showed the expected molecular weight of 59 kDa for CPL, 61 kDa for CPL-K and 62
kDa for CPL-F, respectively, in stain-free sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) gels. Additional bands were also detected around 180 kDa for all constructs, which may
presumably be due to multimerization of the proteins. Dynamic light-scattering (DLS) analysis of
recombinant proteins (of 6 different preparations) in potassium phosphate buffer PPB (pH 8; 22 ◦C)
revealed that CPL, CPL-K and CPL-F form monodispersed solutions (Figure 1c) of small particles with
a hydrodynamic radus of 16.4 ± 0.12 nm (polydispersion (Pd) index = 0.18) for CPL, 19.9 ± 0.13 nm
(Pd index = 0.15) for CPL-K, and 22.5 ± 0.18 nm (Pd index = 0.16) for CPL-F (Figure 1d).
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and 62 kDa (CPL-F). (c) Dynamic light-scattering (DLS) measurement of CPL, CPL-K and CPL-F. 
Measurements were performed three times independently for each of six samples per construct. (d) 
Mean particle sizes detected by DLS in the six samples per construct. Pd, polydispersion; SD, standard 
deviation. 
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ligation assay (PLA) applied to cultured MDA-MB231 cells that naturally express NRP1. We used 
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2.2. CPL-K Interacts with RP1 and Inhibits NRP1 Binding to Plexin A1
We investigated whether CPL-K binds to NRP1 in living cells with a fluorescent proximity ligation
assay (PLA) applied to cultured MDA-MB231 cells that na urally express NRP1. We used specific
antibodies binding to MBP and NR 1, respectively, to re al the int raction b tween th recombinant
protein and the target receptor. Acco ding to the atomic mod l of CP [22], the N- and C-termini of the
CP are very close together. Thus, the N-terminally fused MBP is an excellent reporter for the interaction
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of the C-terminally fused MTP-NRP1 with NRP1-containing receptor complexes in the membrane of
target cells. As shown in Figure 2a, only a few fluorescent spots corresponding to non-specific binding
were detected when 1 µM CPL was added to the cells. However, numerous spots were counted
when MDA-MB231 cells were treated with 1 µM recombinant CPL-K protein, thus reflecting the high
capacity of CPL-K to bind NRP1. The specificity of the interaction was assessed in two independent
shRNA-expressing MDA-MB231 cell lines in which NRP1 was silenced. Indeed, both cell lines (sh1 and
sh2) showed a significantly lower number of spots, suggesting that the amplification signal (red dot)
is generated when CPL-K interacts with NRP1 (Figure 2b,c). To further demonstrate the interaction
of CPL-K with NRP1, we investigated whether CPL-K can inhibit the dimerization of NRP1 with
PlexinA1. Therefore, we determined the number of NRP1/Plexin-A1 dimers at the surface of the
wild-type (WT) cells and in cells knocked down for NRP1. This assay was performed with cells of the
glioblastoma U-118MG cell line previously shown to express NRP1 and Plexin-A1 [54], cells of the
metastatic breast cancer cell line MDA-MB231, and cells with a knockdown of NRP1 expression that
was confirmed by reverse transcription followed by quantitative polymerase chain reaction (RT-qPCR)
analysis in both cell lines (Figure 3a,b). Using the PLA with NRP1 and PlexinA1 antibodies, numerous
fluorescent spots were obtained when MDA-MB231 and U-118MG cells were incubated with CPL,
thus demonstrating that the high level of NRP1/PlexinA1 dimers is not altered by CPL. Incubation of
the cells with CPL-K, however, significantly reduced the number of spots, thereby demonstrating the
disruption of NRP1/Plexin-A1 dimers in both cell types. As expected, cells of the respective NRP1
knockdown lines showed only a low number of spots also in the presence of CPL, confirming the
specific detection of NRP1/Plexin-A1 dimers and their disruption by CPL-K. Quantification of the
spots revealed that CPL-K disrupted the NRP1/Plexin-A1 dimers in the WT cells to the level observed
in the NRP1-silenced cells. Taken together, these observations indicate the capacity of CPL-K to bind
NRP1 and to interfere with the dimerization function of NRP1.
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Figure 2. CPL-K interacts with Neuropilin-1 (NRP1) in MDA-MB-231 cells. (a,b) Proximity ligation
assays (PLA) with MDA-MB-231 cells treated either with 1 µM CPL or 1 µM CPL-K and using antibodies
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against the cellular NRP1 protein together with antibodies against the MBP part of CPL and CPL-K.
NRP1 forms complexes with CPL-K (red fluorescent dots) but not with the CPL control protein.
NRP1/CPL-K complexes are formed in normal cells (a) but not in cells of two different cells lines
in which NRP1 expression is knocked down (sh1, sh2) (b). Scale bar, 10 µm. (c) Quantification of
NRP1/CPL or NRP1/CPL-K interactions (fluorescent dots per cell) in cell lines expressing shRNA
constructs or not (C = control). N = 3 experiments, 5 to 10 imaging fields were quantified per condition
and replicate experiment. * p < 0.05; *** p < 0.0005, ns > 0.05 (non-parametric analysis of variance
(ANOVA) test followed by Dunn’s multiple comparison test).
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Figure 3. CPL-K disrupts NRP1/PlexinA1 co plex for ation. (a,b) Downregulation of NRP1 with
shRNA constructs (sh1, sh2) in MDA-MB231 cells (a) and U-118MG cells (b) as determined by RT-qPCR.
(c–f) Imaging (c,d) and quantification (e,f) of NRP1/PlexinA1 complex formation as determined by PLA
with antibodies for NRP1 and PlexA1 in the presence of 1 µM CPL or CPL-K in MDA-MB-231 (c,e) and
U-118MG cells (d,f) and, upon knockdown of NRP1. Scale bar, 20 µm. ** p < 0.005; ns = not significant
(one-way ANOVA and Dunn’s multiple comparison test).
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2.3. CPL-K Inhibits VEGFA-Induced Tumor Cell Migration and Human Umbilical Vein Endothelial Cell
(HUVEC) Tubulogenesis
We previously showed that the disruption of the NRP1/Plexin-A1 dimer suppresses vascular
endothelial growth factor type A (VEGFA)-induced migration of glioblastoma U-118MG cells [54].
To determine whether the CPL-K-induced disruption of NRP1/Plexin-A1 dimers produces similar
effects on cell migration, we performed a 3D migration assay. Therefore, U-118MG cell aggregates were
grown in plasma clots in the presence or absence of VEGF and in the presence of CPL or CPL-K. As is
shown in Figure 4a,b, VEGFA increased cell migration in comparison to medium alone, as demonstrated
by the more pronounced total surface occupied by migrating cells around the border of the aggregates
after 24 h. Notably, in the presence of CPL-K, VEGFA-induced migration was reduced to levels as seen
without VEGFA, which was not the case in the presence of CPL. The disruption of the NRP1/Plexin-A1
complex was previously also shown to inhibit human umbilical vein endothelial cell (HUVEC) tube
formation on Matrigel [54]. Interestingly, HUVEC Matrigel tubulogenesis assays showed that CPL-K,
but not CPL, has the same effect (Figure 4c,d). Altogether, these results demonstrate that CPL-K
inhibits VEGFA-induced migration and HUVEC tubulogenesis. Importantly, the reduction of HUVEC
tubulogenesis by 37% indicates that the anti-angiogenic activity of CPL-K is similar to that of free
MTP-NRP1, which was shown to inhibit tubulogenesis by 30 % [47].
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Figure 4. CPL-K inhibits cell migration and angiogenesis. (a,b) Phenotype (a) and quantification
(b) of U-118MG cell migration in a 3D coagulated chicken plasma matrix after 24 h of culturing the
cell aggregate. Results are normalized to the cell migration observed in medium without VEGFA.
The relative surface of migration (%) was determined with Image J. N = 3 independent experiments,
5–30 explants measured per condition for each experiment. *** p < 0.0001 ** p < 0.001 Mann-Whitney
test. (c,d) Phenotype (c) and quantification (d) of human umbilical vein endothelial cell ( UVEC)
tubulogenesis on Matrigel 4 h after seeding in complete medium. Scale bar, 200 µ . Results are
nor alized to tubulogenesis in the presence of CPL. Note a 37% decrease of tube formation with CPL-K.
N = 9 independent experi ents. *** p 0.0001; ns = not significant (Mann–Whitney test).
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2.4. CPL-F Binds to NRP1 and Inhibits HUVEC Tubulogenesis
The heptapeptide ATWLPPR was shown to bind NRP1 and to facilitate cellular uptake of a
coupled photosensitizing agent [52,53]. To test the ability of this peptide to guide a tagged CP towards
NRP1, we produced recombinant CPL-F (Find), which carries three consecutive modules of the
ATWLPPR peptide fused to the C-terminus of CP-L. By PLA using antibodies for MBP and NRP1,
we addressed whether CPL-F finds NRP1 and indeed revealed a significant number of interactions
between CPL-F and NRP1 (Figure 5a,b). Next, we wanted to know whether CPL-F had an effect on
HUVEC tubulogenesis, which was again addressed in a Matrigel tubulogenesis assay. As is shown in
Figure 5c,d, CPL-F caused a 52% reduction of HUVEC tube formation.
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Figure 6. CPL-K and CPL-F inhibit Sema3A-induced Akt phosphorylation. (a,b) Representative
Western blot (a) and quantification of Western blot signals (b) of Akt and P-Akt in MDA-MB-231 cells
upon stimulation with Sema3A. Note that Sema3A-induced P-Akt levels are suppressed by CPL-K
and CPL-F but not by CPL. N = 3 experiments. * p < 0.05 (one-way ANOVA and Dunn multiple
comparison test).
2.6. A Nanoparticle Formulation of CPL/CPL-K/CPL-F Inhibits HUVEC Tubulogenesis
So far, we have shown that CPL-F and CPL-K are both active in inhibiting endothelial tubulogenesis.
However, the two proteins likely act differently since CPL-F binds to the extracellular domain of NRP1,
whereas CPL-K interacts with the transmembrane sequences of NRP1. Although both proteins are
active on their own, the question arises whether their effects could be potentiated if combined in the
same nanoparticle. As described in previous reports [32–37], bacterially expressed and purified CP can
be assembled into different aggregates, which is dependent on pH, ionic strength, and temperature.
In designing the nanoparticle, we reasoned that the active molecules (finding and killing moieties)
should be spatially arranged in a way that they could reach their biological target and do not interfere
with each other. Therefore, we combined CPL, CPL-K and CPL-F in equimolar ratios each comprising
one third of the mix. In adaptation to reported conditions for the assembly of bacterially produced
and modified CP [32], we generated disk-like nanoparticles (NPs) by dialyzing CPL as well as the
equimolar mixture of CPL, CPL-K, and CPL-F against 100 mM potassium phosphate pH 8.5 and then,
in a second step, against the same buffer at pH 6.0 and at a temperature of 4 ◦C. The presence of
disk-like NPs formed from CPL alone (CPL-NPs) or from mixtures of CPL, CPL-K, and CPL-F (KF-NPs)
was verified by electron microscopy (Figure 7a). To address whether the KF-NPs retained biological
activity, we tested their effect in HUVEC Matrigel tube formation assays. As depicted in Figure 7b–d,
the KF-NPs exhibited a significant anti-angiogenic effect, whereas CPL-NPs had no effect.
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3. Discussion
In this study we addressed the possibility to generate nanoparticles with anti-cancer properties.
The general strategy was to merge three different tools providing a targeting mechanism (to find
tumor cells), a tumor growth inhibitory mechanism (to kill tumor cells) and a protein scaffold to
assemble the two find and kill moieties. To achieve such a find and kill approach we selected two
types of peptides that previously have been demonstrated to have targeting (ATW-NRP1] [53]) and
inhibitory functions (MTP-NRP1) [47,48] towards NRP1, a key molecule in promoting cancer growth.
Both peptides act at the extracellular and intra-membrane levels without requiring cellular uptake
and are, therefore, useful for the chosen targeting approach. NRP1 is a multivalent transmembrane
receptor interacting with several other transmembrane molecules (mostly receptors) such as Plexin A1
and VEGFR, and soluble binding partners such as Sema3A, amongst others. NRP1 exhibits multiple
functions such as promoting cell migration and angiogenesis, two properties that justify targeting NRP1
for tumor-inhibition [44,56]. As NRP1 is overexpressed in several cancer types [42,43,57], it appears as
an attractive therapeutic target both for reaching the tumor bed and for blocking tumor-cell expansion
in a variety of cancers. Whereas the ATW-NRP1 peptide binds to the ectodomain of NRP1 and has
been previously used as a cancer-targeting tool to enhance the photodynamic destruction of brain
tumors [52,53,58], the hydrophobic MTP-NRP1 targets the transmembrane domain of the receptor [45]
and was shown to efficiently reduce tumor growth in breast- or brain-tumor models [47,48]. However,
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because of its hydrophobic nature, the production and solubilization of MTP-NRP1 is difficult, thereby,
slowing down its development and also presenting a problem in administration. Hence, to succeed in
the production of nanoparticles bearing both the ATW and MTP peptides, we had to select a scaffold
compatible with the opposite biochemical/biophysical properties of the two peptides. We selected
the TMV-derived CP protein that had been linked to a short linker sequence (CP-L) and fused to
MBP to enhance solubility for nanoparticle production. This choice was based on previous reports
having demonstrated that TMV and TMV-derived proteins can be used as carriers to target and deliver
various peptides and proteins [38,59,60]. This approach turned out to be suitable because the CP
fusion proteins displaying either the find (ATW) or the kill (MTP) peptide sequences could easily be
produced. The production reached a high yield with a concentration in the range of mg protein/mL.
In solution, the proteins formed mono-dispersed, individual particles. Importantly, while expected for
CP fusion protein carrying the hydrophilic ATW-NRP1 peptide (CPL-F), the MTP-NRP1 displaying
protein (CPL-K) was also shown to be completely soluble without any requirement of detergent or
solvent that usually is being mandatory for the solubilization of native MTP-NPR1. The removal
of the MBP severely impaired the production of CPL-K. This is in line with our first trials using
engineered TMV for production of the peptides in plants. Here, the high hydrophobicity of MTP-NRP1
led to sequestration of CP by membranes. This blocked the synthesis of the virions, precluding our
attempts to produce CPL-K as part of intact virions in infected plants. Hence, the bacterial approach
we established here solves an important issue for the production and solubilization of MTP-NRP1 and
potentially other peptides that target membrane domain sequences.
Next, we determined whether the particles conserved the biological properties of the MTP and
ATW peptide sequences after fusion with CPL and MBP. The use of a proximity ligation assay (PLA)
confirmed that both the CPL-F and CPL-K particles conserved the capacity of the MTP and ATW
peptides to bind NRP1. The presence of the MBP tag allowed us to detect the CPL-K at the membrane
with specific antibodies, thereby providing the most direct evidence for the interaction of MTP-NRP1
with its target inside the membrane, which previously, with free MTP-NRP1, has been only indirectly
possible by examining the disruption of NRP1 complexes by PLA [53]. The specificity of the CPL-F
and CPL-K binding to the receptor was confirmed by using cells in which NRP1 expression was
knocked-down. Remarkably, we observed a background signal with CPL suggesting that this protein
may stick to the membrane in a non-specific manner. When addressing the interaction of NRP1 with
Plexin-A1 at the cell surface, we demonstrated in cultured U-118MG and MDA-MB-231 cells that
the CPL-K peptide was able to disrupt this interaction. The disruption of this complex presumably
has an impact on the respective downstream signaling. Indeed, by using Sema3A as another NRP1
interactor [61,62], we demonstrated that both CPL-K and CPL-F blocked Sema3A-induced downstream
Akt phosphorylation.
As a potential anti-cancer tool, the CPL-carrying peptides should be able to inhibit cancer relevant
events. Indeed, we showed that the CPL-F and CPL-K reduced tumor cell migration and angiogenesis,
in particular endothelial tube formation. Altogether, these results prove that the CP formulation of
the find and kill peptides conserved their biological properties. Next we examined whether we could
use the self-assembly property of the CP protein to generate multifunctional particles. In adaptation
to the protocol used by Bruckman [32], we produced nano-ring-like structures that we could image
by electron microscopy. In terms of solubility and accessibility of the active sites of the find and
kill peptides in a mixed nanoparticle, the relative ratio of CPL to the two other peptides might be
crucial. We used a one third ratio of each component to minimize cis-interactions between adjacent kill
peptides that may inactivate them. This approach represents a good compromise to retain solubility
and activity. Nanoparticles created by assembling an equimolar mix of CPL-L, CPL-F, and CPL-K
apparently retained a significant anti-angiogenic effect in the HUVEC-based tubulogenesis assays.
This amplitude of inhibition was similar to the inhibition already measured for the individual CPL-F
or CPL-K monomers. A similar range in inhibition (30–50%) has also been observed after siRNA-based
NRP1 silencing [63], thus suggesting that a total inhibition of NRP1-mediated HUVEC tubulogenesis
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is already reached with single NPs. The chosen approach of mixing the proteins does not guarantee a
homogenous and organized distribution of the find and kill sequences within the assembled particles.
Future studies that are beyond the scope of this article have to be carried out to modify the ratio and
array of CPL-F and CPL-K in mixed nanoparticles. Further studies may lead to potential approaches
by which the ratio and array of CPL-F and CPL-K can be determined, optimized, and demonstrated.
It can also be expected that the large MBP moieties present on each of the assembled nanoparticle
subunits hinders the proper display and optimal accessibility of the adjacent active sequences on the
particle surface, which may explain the lack of potentiation that we have observed. Indeed, both the N-
and C-terminus of CP are exposed to the TMV particle surface. Thus, while the MBP moiety attached
to the N-terminus of CPL may be free in its movements and allow the peptides at the C-terminus access
their targets as long as subunits are in monomeric form, particle assembly may impose structural
constraints by which MBP is locked in a position by which it may partially interfere with the activity of
the peptide at the other end. It will be important to further study the assembly and activity profiles of
CPL-K and CPL-F upon removal of MBP or upon application of other solubilizing purification tags.
Nevertheless, we demonstrate here an important starting point to produce complex nanoparticles
decorated with different peptides by simply mixing the different monomers under conditions favorable
for assembly. This concept can now be further developed towards optimization and also for including
other peptides with find and kill properties.
4. Materials and Methods
4.1. Cell Lines
U-118MG and MDA-MB-231 cells were grown in Dulbecco modified Eagle medium (DMEM,
Gibco, Thermo Fisher Scientific, Illkirch-Graffenstaden, France) supplemented with 10% fetal
calf serum (Gibco, Thermo Fisher Scientific), 100 µg/mL streptomycin, and 100 IU/mL penicillin
(Sigma-Aldrich, Saint-Quentin-Fallavier, France). MDA-MB231 RNAi cell lines with reduced NRP1
expression were generated by using NRP1-targeting shRNAs encoded by MISSION Lentiviral
transduction particles (SHCLNV-NM_003873, Sigma-Aldrich). As control for the infected cells,
a lentivirus carrying a GFP reporter was used (MISSION® TurboGFP™ Control Transduction particles
SHC003V, Sigma-Aldrich). Infected cells were selected with puromycin (1 µg/mL). Two of the five
different lentiviruses that were used for NRP1 silencing showed significant reduced expression of
NRP1 (sh1and sh2). NRP1 silencing was determined by RT-qPCR. Here, total RNA was extracted
using TRIzol Reagent® (Invitrogen, Illkirch-Graffenstaden, France) and converted to cDNA with
the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Illkirch-Graffenstaden,
France. Quantitative PCR was performed using the 7500 Real-Time PCR System (Applied
Biosystems) and applying PowerUp™ SYBR™ Green Master Mix together with NRP1 primers
gatcATCCTGATCACCATCATCGCTATGTCTGCTCTGGTTGTTCTGCTGGTTGCTGTTTGCGTTGTT
GTTCTGTACCGTAAACGT and aattACGTTTACGGTACAGAACAACAACGCAAACAGCAACCAG
CAGAACAACCAGAGCAGACATAGCGATGATGGTGATCAGGAT) and the TaqMan™ Fast
Advanced Master Mix together with hGAPDH Taqman probe (Hs02786624_g1) for normalization.
4.2. Plasmids
Bacterial expression plasmids pHis-MBP-CPL, pHis-MBP-CP-L-sNRP1, and pHis-MBP-CPL-3xF
encoding CPL, CPL-K, and CPL-F were created by GatewayTM cloning using sequences of parental
constructs pTMV-L, pTMV-L-NRP1, and pTMV-F. pTMV-L-NRP1 was created by replacing a PacI/KpnI
fragment of the TMV cDNA (in plasmid pUC3/12; [64]) encompassing nucleotides of CP and the
TMV 3’UTR with a synthesized PacI/KpnI fragment (pUC-CP-L-NRP1 based on pUC cloning
vector pIDTSMART:AMP; Integrated DNA Technologies, Leuven, Belgium) and containing the
same part of TMV but in which DNA encoding a flexible linker peptide (GGGGSGGGGSGGGGS)
fused to the DNA encoding the MTP-NRP1 peptide (ILITIIAMSALGVLLGAVCGVVLYRKR) was
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inserted before the CP stop codon. TMV-L-sNrp1 encoding a shorter version of MTP-NRP1
(GVLLGAVCGVVLYRKR), TMV-L not encoding a targeting peptide, and TMV-F encoding
one copy of the ATW peptide (ATWLPPR), were created by PCR using pUC-CP-L-Nrp1 as
template. For TMV-L-sNRP1, pUC-CP-L-NRP1 was used together with overlapping primers
5′-AGGCGGTAGTGGCGGAGGGGGTTCCGGAGTTCTCCTTGGTGCCGTCTGTGG-3′ (forward)
and 5′-CCACAGACGGCACCAAGGAGAACTCCGGAACCCCCTCCGCCACTACCGCCT-3′ (reverse)
to shorten the MTP-NRP1-encoding sequence (sequences encoding part of the NRP1 peptide are
underlined). After PCR, the methylated (parental) DNA was removed by digestion with DpnI.
To remove the NRP1 peptide-encoding sequence from pUC-CP-L-NRP1 and create pUC-CP-L
and pUC-CP-F, the forward primer 5′P-GGTAGTCAAGATGCATAATAAATAACGGATT-3′
was used together with 5′P-GGAACCCCCTCCGCCACTACCGCCTCC-3′ (reverse) or 5′P-
TCTAGGAGGAAGCCAAGTTGCAGTTGCAGGACCAGAGGTCCAAACC-3′ (reverse, sequence
encoding the ATW peptide ATWLPPR is underlined; “P” stands for phosphorylated), respectively.
These primers border the NRP1 sequences to be deleted (for pUC-CP-L) or to be replaced (for
pUC-CP-F) on both sides, thus allowing the rest of the plasmid to be amplified. Both primers were
phosphorylated at the 5’ end to re-circularize the plasmid by ligation (T4 ligase). The plasmids
pUC-CP-L-sNRP1, pUC-CP-L, and pUC-CP-F were digested with PacI and KpnI and the fragments
ligated to the digested TMV, creating the constructs TMV-L-sNRP1, TMV-L, and TMV-F.
To create pHis-MBP-CPL, pHis-MBP-CPL-sNRP1, and pHis-MBP-CPL-3xF, the CPL and CPL-K
fragments were amplified from TMV-L-sNRP1 with the primers (attB1 and attB2 recombination
sites in bold; TEV protease recognition site in italics) 5’GGGGACAAGTTTGTACAAAAAAGCAG
GCTTCGAAAACCTGTACTTCCAGGGTATGGCTTACAGTATCACTACT-3′ (forward) and either
5′-GGGGACCACTTTGTACAAGAAAGCTGGGTTTTAGGAACCCCCTCCGCCACTACC-3′ (for CPL)
or 5′-GGGGACCACTTTGTACAAGAAAGCTGGGTTTTACCTCTTTCTATACAATACCACGCC-3′
(for CPL-K) as reverse primer, and cloned into the donor vector pDONR/Zeo (Thermo Fisher Scientific,
Waltham, MA, USA) to create pDONR-CP-L and pDONR-CP-L-K. CPL-1F was amplified from
TMV-F with primers (attB1 and attB2 recombination sites in bold; TEV protease recognition site in italics)
5′GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAACCTGTACTTCCAGGGTATGGCTTACA
GTATCACTACT-3′ (forward) and 5′GGGGACCACTTTGTACAAGAAAGCTGGGTTTTATCTAGGAG
GAAGCCAAGTTGC-3′ (reverse, sequence encoding the ATW peptide ATWLPPR is underlined)
and introduced into pDONR/Zeo to create pDONR-CP-F. To triplicate the ATW peptide,
pDONR-CP-F was re-amplified with primers (ATW-encoding sequence underlined; “P” indicates
phosphorylated primer) 5′P-GCAACTTGGCTTCCTCCTAGAGCAACTTGGCTTCCTCC-3′ (forward)
and 5′P-TCTAGGAGGAAGCCAAGTTGCAGTTGCAGGACCAGAGGTCC-3′ (reverse), thus adding
one additional copy of the ATW sequence to each side of the existing ATW sequence. Following
ligation, the resulting plasmid pDONR-CP-3xF was re-amplified with primers (linker sequence
is underlined; “P” indicates phosphorylated primer) 5′P- AGGCGGTAGTGGCGGAGGGGGT
TCCGCAACTTGGCTTCCTCCTAGA-3′ (forward,) and 5′P-CCACCAGACCCTCCACCTCCAGTT
GCAGGACCAGAGGTCC-3′ (reverse) to insert the linker (GGGGSGGGGSGGGGS) in front of
the triplicated ATW peptide and creating pDONR-CP-L-3F. The donor plasmids pDONR-CP-L,
pDONR-CP-L-K, and pDONR-CP-L-3xF were finally used for recombination with the destination
vector pDEST-His-MBP (Addgene, Inc., Cambridge, MA, USA; [65]) to create pHis-MBP-CPL,
pHis-MBP-CP-L-sNRP1, and pHis-MBP-CPL-3xF.
4.3. Protein Expression and Purification
The recombinant N-terminally His6-MBP-tagged CPL proteins were expressed in BL21 (DE3) pLysS
(Novagen, Watertown, MA 02472 USA) E. coli cells upon selection with 100µg mL−1 ampicillin. Cultures
(50 mL or 300 mL) were grown for 40 h at 25 ◦C in ZYM5052 auto-inducing media. Upon bacterial
lysis the proteins were purified on a MBP Trap High Performance (HP) column (GE Healthcare Life
Science, Freiburg, Germany) in an ÄKTA Pure chromatography system (GE Healthcare Life Science,
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Freiburg, Germany) and eluted with 10 mM maltose in phosphate-buffered saline (PBS). Peak fractions
were pooled and dialyzed against PBS pH 7.4 using a HiTrap Desalting (DST) column (GE Healthcare
Life Science, Freiburg, Germany). Protein concentrations were determined with NanoDrop 2000
UV-Vis equipment (Thermo Scientific, Wilmington, DE, USA). Protein expression and purification
steps were monitored by analysis of total, soluble and eluted fractions by SDS-PAGE using pre-casted
polyacrylamide gels (PROTEAN TGX Stain-free protein gels, Biorad, Marnes-la-Coquette, France).
4.4. Western Blot for Detection of Akt Phosphorylation
Before protein extraction, cells were treated with CPL-K, CPL-F, or CPL at 10−6 M for 1 h and then
stimulated with Sema3A at 100 ng/mL for 30 min as previously described elsewhere [44]. After lysis
in Laemmli buffer (Sigma) supplemented with protease inhibitors (Roche, Basel, Switzerland) and
phosphatase inhibitor (sodium orthovanadate, Sigma-Aldrich), protein samples were separated in
4–20% pre-casted polyacrylamide gels (PROTEAN TGX Stain-free protein gels, Biorad) by SDS gel
electrophoresis in Tris/Glycine/Sodium Dodecyl Sulfate buffer (Biorad) at 300 V for 18 min. Proteins
were transferred onto nitrocellulose membrane using the Trans-Blot® TurboTM Transfer System
(Trans-blot Turbo, Biorad) and antibodies Akt and phospho-Akt (Cell signaling), and their respective
secondary antibodies coupled with HRP (Biorad) were used. The blots were developed with ECL
(Biorad), imaged with a bio-imager (ChemidocTM Touch Imaging System, Biorad), and normalized
using the stain-free technology (western blot figures can be found in the Supplementary Figure S1).
4.5. Dynamic Light-Scattering (DLS) Analysis
The size distribution profile of particles in the protein solutions was measured by DLS using
Zetasizer Nano Range ZS equipment (Malvern Panalytical, Malvern, UK). 70 µL of the protein solution
(1 mg/mL) was loaded into a cuvette for measurement. The measurements were performed at 22 ◦C in
0.1M potassium phosphate buffer pH8. Particle sizes were analyzed and then expressed in volume
according to the Malvern software instructions.
4.6. Proximity Ligation Assay (PLA)
Cells were seeded on PERMANOX slides (Lab-Tec) overnight, and then treated with 10 µM CPL,
CPL-K or CPL-F monomers for 1 h. After fixation with 1% para-formaldehyde (PFA) for 10 min, cells were
permeabilized with PBS containing 0.1% Triton-x-100. The samples were treated overnight at 4 ◦C in PBS
with appropriate combinations of primary antibodies (mouse anti-NRP1 (Evitria) and rabbit anti-MBP
(New England Biolabs, E8031S) for detection of CPL fusion protein binding to NRP1; mouse anti-NRP1
(Evitria) and rabbit anti-PlexA1 (Abcam, ab23391) for detection of receptor protein dimer disruption).
Subsequent steps of the assay were performed according to the manufacturer’s recommendations
described in the Duolink In Situ Fluorescence Protocol with components of the Duolink PLA and
Duolink In Situ Detection Orange kits (Sigma-Aldrich). Finally, cells were mounted with a coverslip
using Duolink® In Situ Mounting Medium with (4′,6-Diamidine-2′-phenylindole-dihydrochloride
(DAPI, Sigma-Aldrich). Pictures of the labeled cells were taken with an AxioZoom (Zeiss, Axio Imager
Z1, Marly le Roi, France) equipped with appropriate light wavelength filters. Fluorescent signals (dots)
were quantified with ImageJ software (version 1.52, NIH Bethesda, Maryland, USA).
4.7. Cell Migration Assay
Cell migration was analyzed by imaging the number of cells moving away from cell aggregates
formed by the hanging drop method [66]. According to this method, U-118MG cells were cultured
in UMED medium at 37 ◦C and under 5% CO2 using a T75 flask. Upon reaching 70% confluency,
the cells were detached with trypsin (0.05% Trypsin-EDTA 1x, Gibco), collected by centrifugation
(5 min; 800 rpm) at room temperature, and resuspended in 150 µL of UMED medium. A Petri dish of
6 cm diameter was filled with 3 mL of culture medium and 20 µL drops of the cell suspension were
deposited on the internal part of the lid. The lid was then placed to close the dish and to incubate the
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cells above the medium at 37 ◦C and 5% CO2 overnight. The following day, aggregates formed by
the U188 cells were removed and cut into pieces of 30–50 µm (‘explants’). Next, a 12 × 24 mm glass
cover-slip was placed into a 6 cm Petri dish and coated with 20 µL chicken plasma. Subsequently, 15
to 20 ‘explants’ were added onto the plasma. The plasma was then coagulated by addition of 20 µL
thrombin followed by incubation at room temperature. Upon completion of coagulation, DMEM
medium was added into the Petri dish to cover the cells. CPL or CPL-K was added into the culture
medium to a concentration of 10 µM for incubation with the cell aggregates at 37 ◦C and 5% CO2 for
24 h. Microphotographs of the cell aggregates were taken using a Nikon Eclipse TS100 microscope
(Nikon, Champigny sur Marne, France) and the area around the aggregates covered with migrated
cells was determined with ImageJ software.
4.8. Angiogenesis Assay
Human umbilical vein endothelial cells (HUVECs) were cultured at 37 ◦C under 5% CO2 in
endothelial cell culture medium (PromoCell, Heidelberg, Germany) supplemented with endothelial
cell growth supplement (ECGS; 4 µL/mL), fetal calf serum (FCS, 20 µL/mL, Thermo Fisher Scientific),
human epidermal growth factor (hEGF; 0.1 ng/mL), and human basic fibroblast growth factor (hbFGF;
1 ng/mL, Thermo Fisher Scientific). For the assay, plates (15 u-slide Angiogenesis, Ibidi plates, Biovalley,
Nanterre, France) were coated with Matrigel (Merck-Millipore, Billerica, MA, USA) at 37 ◦C for 1 h.
Subsequently, 5000 HUVECs in culture medium (50 µL) with the CPL proteins at 10−6 M were added
to each well for 3 h (37 ◦C, 5% CO2). The cells in each well were imaged by DIC microscopy (Leitz DM
RB, Leica, Nanterre, France) and the number of closed tubes was counted for 5 wells per condition.
4.9. Disk Assembly
To assemble disk oligomers from hybrid CP monomers, the monomer concentration was set
to 2 mg/mL prior to dialysis, as recommended [32]. The samples were initially dialyzed against
100 mM potassium phosphate pH 8.5 at 4 ◦C for 24 h in a Slide-A-Lyzer MINI dialysis unit (Thermo
Fisher Scientific) with a 10 kDa molecular weight cutoff (MWCO). For assembly, the samples were
subsequently dialyzed against 100 mM potassium phosphate pH 6 at 4◦ C for 24 h. To assemble disks
from different monomers, equal volumes of the different CPL proteins in 100 mM potassium phosphate
pH 8.5 were mixed and the mixed sample was dialyzed against 100 mM potassium phosphate pH 6
for 24 h. Before angiogenesis assays, non-assembled monomers were removed by filtering through
Vivaspin 500 columns with a MWCO of 100 kDa (GE Healthcare, Strasbourg, France).
4.10. Transmission Electron Microscopy (TEM) Imaging
An 8 µL protein sample was deposited onto a Formvar coated nickel grid for 1 minute. Excess
solution was removed with filter paper. The grid was stained with uranyl acetate (15 µL at 2%) and the
excess of stain was removed and dried. Subsequently, the sample was observed with a Hitachi H7500
transmission electron microscope (TEM) at 80kV.
4.11. Statistical Analysis
Data were analyzed with GraphPad (Prism 5, San Diego, CA, USA). Statistical analyses were
performed using Mann-Whitney test (for sample n < 30) and one-way analysis of variance (ANOVA)
for comparison between groups. Results are given as mean ±SD and considered significant for p < 0.05.
5. Conclusions
Our data demonstrate that the TMV CP protein fused with MBP protein at its N-terminus and
with a flexible linker at its C-terminus can be used as a nanocarrier and scaffold to assemble particles
displaying peptides with hydrophilic or hydrophobic properties. This polyvalent platform offers
unprecedented possibilities to generate smart nanoparticles in high yields and concentration. Presented
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here in the form of anti-cancer particles with a find and kill potential, the variation of the types of
peptides that can be incorporated is probably unlimited.
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